Knockout of the ATPase inhibitory factor 1 protects the heart from pressure overload-induced cardiac hypertrophy

Kevin Yang1, Qinqiang Long1,2, Kamalamma Saja1,3, Fengyuan Huang1, Steven M. Pogwizd4, Lufang Zhou5, Masasuke Yoshida5 & Qinglin Yang1,2

Mitochondrial ATP synthase catalyzes the coupling of oxidative phosphorylation. Under pathological conditions, ATP synthase hydrolyzes ATP to replenish protons from the matrix into the intermembrane space, sustaining mitochondrial membrane potential. ATPase inhibitory factor 1 (IF1) is a nuclear-encoded, ATP synthase-interacting protein that selectively inhibits the hydrolysis activity of ATP synthase, which may render the protective role of IF1 in ischemic hearts. However, the in vivo cardiac function of IF1 and the potential therapeutic application targeting IF1 remain obscure. In the present study, we uncovered that IF1 is upregulated in mouse hearts with pressure overload-induced hypertrophy and in human hearts with dilated cardiomyopathy. IF1 knockout (KO) mice were protected against cardiac dysfunction and pathological development induced by transverse aortic constriction (TAC) or isoproterenol infusion. The reduced ATP hydrolysis activated AMPK activity in IF1 KO hearts, which together facilitated autophagy. These results suggest that IF1 upregulation in the failing heart may be a maladaptive response. Inhibiting IF1 in the hypertrophied heart not only prevents cell death from excessive mitochondrial depolarization but also activates AMPK signaling and increases autophagy. Therefore, IF1 inhibition may serve as a potential therapeutic target in treating pathological cardiac hypertrophy and heart failure.

Prolonged cardiac hypertrophy in response to pathological stresses is the main risk factor for congestive heart failure, a leading cause of mortality and morbidity1. Despite substantial advances in therapy, successful treatment of pathological hypertrophy and heart failure remains challenging.

Mitochondria play a pivotal role in cellular energy status and cell fate. ATP synthase is a crucial protein complex in the mitochondria that couples osmo-chemical energy into ATP. ATP synthase not only regulates the production and hydrolysis of ATP in mitochondria but also is a key regulatory mechanism of mitochondrial membrane potential (ΔΨm)2,3. ATP synthase consists of two sub-complexes with distinct but complementary functions. The Fo complex contains transmembrane subunits that transport protons, while the F1 is a peripheral complex on the matrix side that contains the catalytic nucleotide binding sites for ATP synthesis4–7. Fo and F1 are coupled through two stalk-like subunit connections: a central rotor shaft and a peripheral stator4. Despite the well-recognized role of the ATP synthase in energy metabolism, the effect of changes in ATP synthase activities on cardiac pathogenesis remains obscure.

The inhibitory factor 1 (IF1) is a nuclear-encoded ATP synthase interacting protein that suppresses the hydrolysis activity of ATP synthase8,9 under acidic conditions, such as in myocardial ischemia10–12. The roles of IF1 in various tissues remain controversial. It has been shown that IF1 mimetic compounds improve cardiac function in isolated heart subjected to ischemia-reperfusion13,14. Transgenic overexpression of a mutant IF1 protects...
neuronal damages15. IF1 deficiency has been linked to anemia due to impaired heme synthesis16. In contrast, loss of IF1 in mice strongly protects against antimycin-induced electron transport chain dysfunction and cell death17. The apparently contradicting effects of IF1 in various tissues are puzzling and further studies are warranted.

While IF1 knockout in mice leads to no overt phenotype18, it remains unclear if IF1 in the in vivo heart becomes crucial in maintaining cardiac function under pathological stresses.

In the present study, we hypothesize that cardiac IF1 regulates mitochondrial polarization, energetic function and cell fate in pathological hypertrophy as an ATPase inhibitor of ATP synthase. To test this hypothesis, we investigate how the loss of cardiac IF1 affects cardiac structure/function in response to pathological stimuli and define the underlying molecular and biochemical mechanisms.

Results

IF1 protein expression is upregulated in pressure overload-induced hypertrophied hearts. We first investigated cardiac IF1 expression in the normal and hypertrophic hearts. Real-time PCR revealed that IF1 mRNA was upregulated in the heart in response to TAC-induced pressure overload (Fig. 1A). Western blot analysis demonstrated IF1 protein levels increased almost 2-fold in hypertrophied compared with the sham control hearts (Fig. 1B). Western blot analysis on protein lysates from patients with dilated cardiomyopathy and healthy donors revealed that cardiac IF1 protein was upregulated by about 55% in human failing hearts compared to non-failing donor hearts by about 55% (Fig. 1C). These results provide the first evidence that cardiac IF1 is upregulated in pathologic hearts.

Figure 1. IF1 expression in the pathological heart. (A) Transcript expression of IF1 was determined by real-time PCR. Transcript level of β-actin was used as loading control. Mice were subjected to 4 weeks of TAC. RNA was extracted from LV tissue (n = 4). (B) Protein expression of IF1 and ATP5B were determined by Western blot. Actin was used as protein loading control. The ratio of IF1/ATP5B is shown. Mice were subjected to 4 weeks of TAC. Protein was extracted from LV tissue (n = 4). (C) Protein expression of IF1 was determined by Western blot. Actin was used as protein loading control. Protein lysates were obtained from heart samples from heart failure patients and healthy donors (n = 4). *P < 0.05 vs sham. Data are expressed as mean ± SEM.

IF1 deficiency protects the heart against pressure overload hypertrophy. We further confirmed the previous finding19 that no overt phenotype was present in IF1 KO mice up to 8 months of age. IF1 KO mice (10–12-week-old) were subjected to TAC-induced pressure overload for 4 weeks. Echocardiographic assessment confirmed a sustained LV pressure overload with an average intraventricular pressure gradient of ~40 mmHg (Table 1). Furthermore, cardiac contraction, as indicated by fractional shortening and ejection fraction, was improved in IF1 KO relative to the wild type hearts (Fig. 2A,B). TAC-pressure overload induced a substantial increase of inter-ventricular septum (IVS) and posterior wall thickness (LVPW) at both systole and diastole in WT, but not in IF1 KO mice (Table 1). Interventricular dimensions (LVID) at systole and diastole were increased in WT, but not in IF1 KO mice (Table 1). Heart weight to body weight and heart weight to tibia length ratios were lower in the IF1 KO than in the WT hearts (Fig. 2C,D). Furthermore, Real-timePCR revealed that cardiac expression of molecular markers of cardiac hypertrophy, such as natriuretic peptide A (Nppa) and B (Nppb),
Loss of IF1 activates the AMPK pathway and induces autophagy in the heart. Western blot analyses showed that the phosphorylation of AMPK was increased on protein samples from IF1 KO compared to WT hearts. This suggests that AMPK is activated in response to loss of IF1. The phosphorylation of Akt showed no difference between IF1 KO and WT mouse hearts subjected to TAC (Fig. 6B). Further, Western blot analyses revealed a substantially increased LC3-II in IF1 KO compared with WT mouse hearts subjected to TAC, while the total AMPK protein level remained the same (Fig. 6A). The resulting increase in pAMPK/AMPK ratio indicates the activation of AMPK in IF1 KO hearts. On the other hand, the phosphorylation of Akt showed no difference between IF1 KO and WT mouse hearts subjected to TAC (Fig. 6B). These results suggest that autophagic flux is activated in IF1 deficient hearts under the pressure overload condition.

Discussion
We demonstrate for the first time that cardiac expression of IF1 is upregulated in pressure overload hearts. While there is no basal phenotype, the loss of IF1 protects the mouse heart from pressure overload hypertrophy. The loss of IF1 prevents excessive depolarization of the mitochondrial membrane and optimizes cardiac energy homeostasis with AMPK activation. These findings suggest a maladaptive response of IF1 upregulation in the chronically stressed heart.

It has been well documented that IF1 suppresses the hydrolysis activity of ATP synthase under acidic conditions such as myocardial ischemia, thus preserving ATP. When mitochondrial depolarization occurs in pathological conditions, such as myocardial ischemia, cardiac IF1 is suggested to be activated to inhibit ATP hydrolysis of ATP synthase. Inhibiting ATP hydrolysis has been proposed to be a potential clinical strategy for...

Table 1. Echocardiography measurement in mice with pressure overload. Abbreviations: IVSs and IVSd: interventricular septal wall thickness (systole and diastole); LVPWs and LVPWd: posterior wall thickness at systole and diastole; *P < 0.05 vs sham, †P < 0.05 vs WT TAC. Data are expressed as mean ± SEM.

| Parameters         | WT Sham (n = 5) | WT TAC (n = 7) | IF1 KO Sham (n = 6) | IF1 KO TAC (n = 9) |
|--------------------|----------------|---------------|--------------------|-------------------|
| IVSd, mm           | 0.67 ± 0.06    | 0.92 ± 0.10†  | 0.69 ± 0.08        | 0.80 ± 0.11       |
| IVSs, mm           | 0.97 ± 0.04    | 1.38 ± 0.11†  | 1.13 ± 0.07        | 1.16 ± 0.15       |
| LVIDd, mm          | 4.19 ± 0.10    | 4.48 ± 0.16†  | 4.17 ± 0.11        | 4.04 ± 0.07†      |
| LVIDs, mm          | 2.90 ± 0.08    | 3.52 ± 0.14†  | 2.96 ± 0.07        | 2.97 ± 0.06†      |
| LVPWd, mm          | 0.46 ± 0.04    | 0.87 ± 0.09†  | 0.51 ± 0.03        | 0.73 ± 0.06†      |
| LVPWs, mm          | 0.69 ± 0.06    | 1.01 ± 0.10†  | 0.80 ± 0.04        | 0.92 ± 0.05       |
| LV mass, mg        | 42.40 ± 5.60   | 92.36 ± 12.68*| 44.75 ± 3.25       | 60.30 ± 3.42*     |
| Pressure Gradient, mmHg | NA           | 40.25 ± 3.37 | NA                 | 46.99 ± 1.09      |

Post-TAC WT hearts (Fig. 3F).

Blot showed reduced cleavage (17 KD) of caspase-3 on the protein extracts from post-TAC IF1 KO compared to WT hearts (Fig. 3D,E). Consistently, Western blot analysis of heart sections from IF1 KO revealed a substantially enhanced LC3-II compared to WT mice after TAC (Fig. 3F). These results suggest that autophagic flux is activated in IF1 deficient hearts under the pressure overload condition.

IF1 KO protects the heart from mitochondrial depolarization. After confirming the complete IF1 KO in the heart, we conducted in-gel ATPase staining on mitochondrial extracts confirming an increase of ATPase activity in the IF1 KO (Fig. 5A). Quantitative JC-1 assay on mitochondria isolated from mouse hearts showed no ΔΨm change in IF1 KO compared with WT hearts subjected to sham procedure (Fig. 5B), whereas ΔΨm loss in IF1 KO was less pronounced than that in WT mitochondria from mice subjected to TAC (Fig. 5B). In a stable IF1 knockdown (KD) H9C2 cell line (Fig. 5C), ATP assay revealed a substantial reduction of ATP content in IF1 KD H9C2 cells (Fig. 5D). JC-1 assay consistently showed IF1 KD H9C2 cells had a less pronounced isoproterenol (1 μmol/L for 24 hours)-induced ΔΨm reduction than scramble shRNA H9C2 cells (Fig. 5E). These results indicate that pathological stress-induced mitochondrial depolarization is relatively sustained in IF1 deficient hearts.

Western blot analyses revealed a substantially increased LC3-II in IF1 KO compared with WT hearts subjected to TAC (Fig. 6C). Protein levels of p62 were decreased and Beclin-1 were increased in IF1 KO compared to WT hearts after TAC (Fig. 6D,E). As a result, the ratio of p62 to Beclin-1 was markedly decreased (Fig. 6F). These results suggest that autophagic flux is activated in IF1 deficient hearts under the pressure overload condition.

Discussion
We demonstrate for the first time that cardiac expression of IF1 is upregulated in pressure overload hearts. While there is no basal phenotype, the loss of IF1 protects the mouse heart from pressure overload hypertrophy. The loss of IF1 prevents excessive depolarization of the mitochondrial membrane and optimizes cardiac energy homeostasis with AMPK activation. These findings suggest a maladaptive response of IF1 upregulation in the chronically stressed heart.

It has been well documented that IF1 suppresses the hydrolysis activity of ATP synthase under acidic conditions such as myocardial ischemia, thus preserving ATP. When mitochondrial depolarization occurs in pathological conditions, such as myocardial ischemia, cardiac IF1 is suggested to be activated to inhibit ATP hydrolysis of ATP synthase. Inhibiting ATP hydrolysis has been proposed to be a potential clinical strategy for...
treating various pathological conditions\textsuperscript{15,20}, including myocardial ischemia-reperfusion injury\textsuperscript{13,14}. IF1 mimetic compounds, e.g., BMS-199264 and BMS-250685, have been shown to enhance cardiac performance in isolated heart subjected to myocardial ischemia/reperfusion\textsuperscript{13,14,21}. Before further exploiting IF1 as a therapeutic target for heart diseases, it is essential to obtain the \textit{in vivo} expression and function of IF1 in the pathological heart. Since the nuclear factor (NF)-κB regulates the transcriptional expression of IF1\textsuperscript{22} and NF-κB has been well documented to be activated in the hypertrophied and failing hearts\textsuperscript{23,24}, the upregulation of IF1 is possibly derived from the activation of NF-κB. Protein kinase A (PKA)-mediated IF1 phosphorylation may reduce IF1’s binding to ATP synthase F1 sector\textsuperscript{25}. It is plausible that IF1 KO may avoid a potentially harmful effect derived from the accumulation of unbound IF1 in the hypertrophic heart as a result of PKA activation. Further studies should clarify the upstream signaling pathways and how PKA phosphorylated IF1 may attribute to cardiac pathology.

The \textit{in vivo} role of IF1 remains understudied. Recently, several mouse lines were generated with IF1 KO\textsuperscript{17,18} or an inducible, neuron-specific overexpression of a mutant IF1 (H49K) with a higher binding affinity for the α-catalytic subunit of the ATP synthase\textsuperscript{15}. Two independent IF1 KO lines similarly showed no basal phenotypic changes at least before aging\textsuperscript{17,18}, confirming that IF1 is not essential for normal development and reproduction of mice. It is interesting that neuron-specific overexpression of a mutant IF1 (H49K) with a higher binding affinity

Figure 2. Echocardiographic parameters in mice with pressure overload. (A) and (B) echocardiographic results of ejection fraction (%), and fractional shortening (%) are shown 4 weeks after TAC (n = 5–9). (C) Ratio of heart weight (mg) to body weight (g). (D) Ratio of heart weight (mg) to tibia length (mm). (E) and (F) Real-time PCR assessment of natriuretic peptide A and B transcript expression normalized to 36B4. RNA was extracted from LV tissue of hearts subjected to 4 weeks of TAC (n = 4). *P < 0.05 vs sham, #P < 0.05 vs WT TAC. Data are expressed as mean ± SEM.
for the β-catalytic subunit of the ATP synthase is neuron-protective due to a preconditioning effect in response to elevated reactive oxygen species (ROS). Studies on cultured mammalian cells and zebrafish showed that IF1 deficiency may impair heme synthesis as a result of mitochondrial pH elevation following the reversed proton flow. In contrast, a recent study showed that inhibiting IF1 is beneficial in protecting severe mitochondrial respiratory chain dysfunction by reducing mitochondrial depolarization and apoptotic cell death in hepatic cells. Results from the present study appear to support the protective role of IF1 knockout in the pathological heart. The present study on the mouse model of IF1 KO provides new insights into the potential effects of blocking IF1 in the in vivo heart under a mechanical stress condition and sheds new light on the mechanistic actions of IF1 in regulating mitochondrial function and cell survival signaling.
Figure 4. Echocardiographic parameters of mice after 2 weeks of isoproterenol infusion. (A) Ratio of LV mass (mg) to body weight (g) (n = 7). (B) and (C) Echocardiographic results of fractional shortening (%) and ejection fraction (%) are shown (n = 7). *P < 0.05 vs Before Isoproterenol, †P < 0.05 vs WT ISO. Data are expressed as mean ± SEM.

| Parameters             | Before Isoproterenol | After Isoproterenol (2 weeks) |
|------------------------|----------------------|-------------------------------|
|                        | WT (n = 7)           | IFL1 KO (n = 7)               | WT (n = 7) | IFL1 KO (n = 7) |
| LVID;s (mm)            | 3.22 ± 0.08          | 3.20 ± 0.11                   | 3.60 ± 0.11* | 2.96 ± 0.11† |
| LVID;d (mm)            | 4.31 ± 0.09          | 4.29 ± 0.10                   | 4.76 ± 0.11* | 4.33 ± 0.10† |
| IVS;s (mm)             | 1.13 ± 0.04          | 1.08 ± 0.03                   | 1.25 ± 0.04 | 1.36 ± 0.03     |
| IVS;d (mm)             | 1.03 ± 0.06          | 0.96 ± 0.04                   | 1.09 ± 0.04 | 1.23 ± 0.03     |
| LVPWs (mm)             | 0.88 ± 0.05          | 0.92 ± 0.07                   | 0.85 ± 0.04 | 1.07 ± 0.07†    |
| LVPW;d (mm)            | 0.63 ± 0.06          | 0.71 ± 0.09                   | 0.57 ± 0.03 | 0.77 ± 0.05     |

Table 2. Echocardiography measurement in mice with isoproterenol infusion. Abbreviations: IVS;s and IVS;d: interventricular septal wall thickness (systole and diastole); LVIS;s and LVID;d: left ventricular dimension at systole and diastole; LVPWs and LVPW;d: posterior wall thickness at systole and diastole; *P < 0.05 vs Before Isoproterenol, †P < 0.05 vs WT ISO. Data are expressed as mean ± SEM.
Mitochondrial ATP synthase is an enzyme catalyzing the final coupling step of oxidative energy production. Alterations at this crucial step of oxidative phosphorylation have major impacts on cellular energy supply and mitochondrial energetic homeostasis. This is especially the case in the energy-craving heart under pathological conditions. Under hypoxic conditions, the mitochondrial ATP synthase hydrolyzes ATP to replenish protons from the matrix into the intermembrane space to maintain mitochondrial membrane potential10, 13, 26. Therefore, ATP synthase is one of the key regulating points of $\Delta \Psi_m$. Severe membrane depolarization not only impairs mitochondrial respiration, but also leads to programmed cell death, as well as a net loss of functional myocardium. At least in the in vitro cell culture experiment, IF1 overexpression depolarizes the mitochondria as predicted due to a repression of ATP hydrolysis. On the other hand, we observed a lesser degree of mitochondrial depolarization in IF1 KO mitochondria and in IF1 knockdown H9C2 cells, which is most likely due to the increase of reversed proton flow into the mitochondrial intermembrane space as a consequence of elevated ATP hydrolysis. As a result, $\Delta \Psi_m$ in IF1 KO hearts is ultimately more resistant to pressure overload and isoproterenol-induced stresses that lead to the depolarization and the subsequent cell death. IF1 may play a role in facilitating mitochondrial cristae formation and EM assessment of ultrastructure of IF1 KO liver showed loss of

Figure 5. Effects of IF1 deficiency on ATP synthase activity and mitochondrial membrane potential. (A) In gel ATPase assay on LV mitochondria isolated from mice subjected to 4-week pressure overload (n = 4). (B) JC1 assay for mitochondrial membrane potential ($\Delta \Psi_m$) on LV mitochondria isolated from mice subjected to 4-week pressure overload (n = 6). (C) Western blot analysis of IF1 on protein samples from stable IF1 KD and control H9C2 cells. Protein loading was normalized to actin. (D) ATP content in stable IF1 KD and control H9C2 cells (n = 5). (E) JC-1 assay for $\Delta \Psi_m$ on H9C2 cells treated with isoproterenol (n = 5). *P < 0.05 vs sham, #P < 0.05 vs WT TAC. Data are expressed as mean ± SEM.
However, our study showed that mitochondrial ultrastructure is normal in IF1 KO hearts under both basal and pressure overload condition. While further studies are warranted, it is plausible that factors other than IF1 may be sufficient to maintain mitochondrial integrity in the heart.

Figure 6. AMPK activity and autophagy in mice with pressure overload. Western blot was conducted on protein samples extracted from LV tissue of hearts subjected to TAC for 4 weeks. (A) Protein expression of pAMPK and AMPK. pAMPK to AMPK ratio is shown (n = 4). (B) Protein expression of pAKT and AKT. pAKT to AKT ratio is shown. (C) Protein expression of LC3. LC3-II protein levels were normalized to GAPDH (n = 4). (D) Protein expression of p62. Expression was normalized to GAPDH (n = 4). (E) Protein expression of Beclin-1. Expression was normalized to Actin (n = 4). (F) Ratio of p62 to Beclin-1 protein expression. *P < 0.05 vs WT TAC. Data are expressed as mean ± SEM.
The downside to sustaining $\Delta V_m$ by repressing IF1 is the elevated consumption of ATP, which in turn activates the energy sensor complex, AMPK. AMPK activation has been shown to promote cellular autophagy by inhibiting the mammalian target of rapamycin (mTOR) signaling\(^\text{28}\). On the other hand, we did not detect changes in the activity of AKT (a serine/threonine kinase also known as protein kinase B [PKB]). AKT is a downstream protein in the phosphatidylinositol 3-kinase (PI3K) pathway, which is known to activate mTOR signaling. As expected, we did detect an increase of LC3-II and beclin-1, and a decrease of p62 in IF1 KO hearts subjected to pressure overload. In addition to the evidence of increased degradation of p62, the markedly decreased p62 to beclin-1 ratio supports an elevating autophagic flux\(^\text{29}\).

In conclusion, the myocardial protective effect of IF1 deficiency is not only related to its effects of maintaining $\Delta V_m$, but also to the AMPK-mediated upregulation of autophagy flux. Potential interventions that could inhibit IF1 should be beneficial. Therefore, IF1 inhibition may serve as a potential therapeutic target in treating pathological cardiac hypertrophy and heart failure.

Methods

Transverse aortic constriction (TAC) procedure to induce left ventricular (LV) pressure overload hypertrophy. Pressure overload-induced hypertrophy was created by transverse aortic constriction (TAC) as described previously\(^\text{30}\). Briefly, three-month-old (male and female) IF1 KO and WT mice (C57/B6) were anesthetized and maintained by isoflurane inhalation. After a minimal chest opening, the transverse aorta was ligated by tying a 6–0 silk suture against a 26-gauge needle. Sham mice underwent the same procedure without ligation of the aorta. The above mice were sacrificed 4 weeks after TAC or sham operation. All experimental procedures were conducted in accordance with the Guide for Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.

Isoproterenol infusion in mice. Three-month-old IF1 KO and WT mice (C57/B6) were infused with isoproterenol (ISO) (60 mg/kg/day) for 14 days. Alzet miniosmotic pumps (no. 2002; Alza Corp., Mountain View, California) containing either ISO or PBS were surgically inserted subcutaneously on the back under isoflurane anesthesia. All mice were sacrificed 2 weeks later.

Cardiac mitochondrial Isolation. Mitochondria were isolated using the Mitochondrial Isolation Kit (Pierce) according to the manufacturer’s instructions\(^\text{31}\). Briefly, LV tissues from a single heart were washed and minced in 800 μl of Reagent A plus protease inhibitor cocktail (Sigma). The minced tissue was stroked 10 times with a Dounce homogenizer. The homogenate was centrifuged for 10 min at 700 g in 4 °C. The supernatant solution was transferred to a new chilled tube, and centrifuged for 15 min at 3,000 g in 4 °C. The cytosolic fraction was saved and stored at −80 °C and the pellet was washed with 500 μl of Wash Buffer and centrifuged for 5 min at 12,000 g in 4 °C. The final washed pellet was suspended in 100 μl of Reagent A containing protease inhibitor cocktail. Mitochondrial protein concentration was determined using the Lowry method.

In-gel ATPase activity assay. BN-PAGE was used to resolve the native, intact mitochondrial protein complexes as described previously\(^\text{32}\). ATP hydrolysis activity was measured following BN-PAGE as described above. After completion of BN-PAGE, the gel was briefly incubated in assay buffer (35 mmol/L Tris/Cl, 270 mmol/L glycine, 14 mmol/L MgSO\(_4\), 0.2% (w/v) Pb(NO\(_3\))\(_2\), 8 mmol/L ATP, pH 8.3) at varying time courses. Gels were fixed in 50% methanol and washed twice in ddH\(_2\)O for 10 min and then scanned. The lead precipitates were quantified based on densitometry.

Quantitative Real-time PCR. Total RNA samples were isolated from LV using a RNA extraction kit (Zymo) according to the manufacturer’s instructions. Quantitative real-time PCR analyses were carried out using the Step One Real-time PCR system (Applied Biosystems) to determine transcript levels of target genes. Expression of each gene was normalized to actin or 36B4, and compared across conditions. The primer pairs used for Real-Time PCR analyses were: IF1: TTCGGTGTCGGGGTATGAAG/GCCCGTATCCATGCTATCCG; Nppa: GGGAGAACACGGCATCAT/CGTGATAGATGAAGGCAGGAA; Nppb: GGGAGAACACGGCATCAT/GCGTGATAGATGAAGGCAGGAA; 36B4: TGGAGACAAGGTGGGAGCC/CACAGACAATGCCAGGACGC

Protein extraction and Western blot analysis. We extracted total protein, mitochondrial and cytosolic proteins from mouse LV or cells, separated by SDS-PAGE, and performed immunoblot analyses. Human protein lysate was obtained from diluted cardiomyopathy patients and healthy donors, as approved by the UAB Institutional Review Board for Human Use. Informed consent for use of samples was obtained for all participants and/or their legal guardians. Proteins were transferred onto PVDF membranes and immunoblot analyses were carried out using antibodies from commercial sources: IF1 (Santa Cruz, mAb); pAMPK (CST, mAb); AMPK (CST, mAb); pAKT (CST, mAb); AKT (CST, mAb); caspase-3 (CST, pAb); LC3 (MBL, pAb); p62 (CST, pAb); Beclin-1 (ThermoFisher, pAb); ATP5B (Abcam, mAb); actin (Sigma, mAb); GAPDH (Santa Cruz, pAb), following the manufacturer’s instructions. The immunoblotting images were captured with Chemidoc MP System (Bio-Rad) by developing the membranes in Luminata Western Chemiluminescent HRP Substrates (Millipore).

Echocardiography measurement. We assessed the mouse cardiac structure and cardiac function using a high-resolution echocardiograph system (Visualsonic VEVO 770 System) as previously described\(^\text{30, 33, 34}\). Briefly, mice were anesthetized with isoflurane inhalation. Heart rate was maintained at ~400 BPM and body temperature was maintained at 37 °C by placing mice on a heating pad. With a 35 MHz probe on long-axis and short axis M-mode images, we measured the thickness of interventricular septum (IVS) and LV posterior wall (LVPW), as well as LV internal diameter (LVID) at diastolic and systolic states. We analyzed the above data using the
Advanced Cardiovascular Software package from the manufacturer to obtain parameters such as EF%, FS% and calibrated LV mass.

**Pathological examinations.** Hearts were perfused and fixed using standard methods for pathological examinations by light microscope and transmission electron microscopy (TEM) that was processed in the High-Resolution Imaging Facility of the University of Alabama at Birmingham. Heart sections were processed and stained with hematoxylin/eosin (H/E) or Masson's Trichrome blue in the Comparative Pathology Laboratory of the University of Alabama at Birmingham.

**JC-1 assay for mitochondrial potential (ΔΨm).** Mitochondria potential (ΔΨm) was determined using the JC-1 assay kit (Sigma) according to the manufacturer's instruction. Cultured H9C2 cells or isolated mitochondria (10µg) from IF1 KO and WT mice were treated with 5µM JC-1 for 10 minutes. The relative fluorescence of the sample was measured in a multimode microplate reader (Infinite 200, Tecan) with 485/535 nm excitation and 535/595 nm emission.

**Apoptosis detection.** Apoptotic cardiomyocytes in frozen heart section were identified with TUNEL assay using the Click-IT TUNEL Alexa Fluor Imaging Assay Kit (Life technologies). Caspase-3 cleavage was detected via Western Blot analyses of protein expression, and analyzed as expression of cleaved caspase-3 compared to actin.

**Generation of stable ATPIF1 knockdown H9c2 cell line.** H9C2 cardiomyocytes (ATCC CRL-1446, rat embryonic heart myoblasts) were transfected with short hairpin RNA (shRNA) constructs against ATPIF1 in pRS (shATPIF1-pRS) vector (OriGene Technologies, Rockville, MD) using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. The ATPIF1 targeting sequences that we validated for the successful knockdown of ATPIF1 expression are GGCGCTGGCTCCATCCGAGAAGCTGGTGG (cat# TG709527B) and ACTCTGCGGAGACATGGATTCGGGCGCT (cat# TG709527C). Forty-eight hours after transfection, the cells were selected with puromycin (0.5µg/mL) in the growth DMEM medium for 4 weeks to obtain a stable cell line. Surviving cells were examined for the level of ATPIF1 expression by Western blot and further expanded for functional analysis.

**ATP assay.** Relative ATP levels were assessed with the ATPLite Luminescence Assay System (PerkinElmer), according to the manufacturer's instructions. Cultured H9C2 cells were treated with cell lysis and substrate solution. The relative luminescence of the sample was measured in a multimode microplate reader (Infinite 200, Tecan).

**Statistical analyses.** Data for 2-group comparisons were analyzed with the nonparametric two-tailed Student t-test; otherwise, data were analyzed by one-factor or mixed, 2-factor ANOVA and multiple comparison using the GraphPad Prism 6 software (GraphPad Software Inc.). Values of quantitative results were expressed as mean ± SEM. Differences between groups and treatments were regarded as significant at p < 0.05.

**References**

1. Roger, V. L. Epidemiology of heart failure. Circulation research 113, 646–659 (2013).
2. Appleby, R. D. et al. Quantitation and origin of the mitochondrial membrane potential in human cells lacking mitochondrial DNA. Eur J Biochem 262, 108–116 (1999).
3. Lefebvre, V. et al. Genome-wide RNAi screen identifies ATPase inhibitory factor 1 (ATPIF1) as essential for PARK2 recruitment and mitophagy. Autophagy 9, 1770–1779 (2013).
4. Abrahams, J. P., Leslie, A. G., Lutter, R. & Walker, J. E. Structure at 2.8 A resolution of F1-ATPase from bovine heart mitochondria. Nature 370, 621–628 (1994).
5. van Raaij, M. J., Abrahams, J. P., Leslie, A. G. & Walker, J. E. The structure of bovine F1-ATPase complexed with the antibiotic inhibitor aurovertin B. Proceedings of the National Academy of Sciences of the United States of America 93, 6913–6917 (1996).
6. Chen, C. et al. Mitochondrial ATP synthase: three-dimensional structure by electron microscopy of the ATP synthase in complex formation with carriers for Pi and ADP/ATP. The journal of biological chemistry 279, 31761–31768 (2004).
7. Chen, C. et al. Mitochondrial ATP synthase. Crystal structure of the catalytic F1 unit in a vanadate-induced transition-like state and implications for mechanism. The journal of biological chemistry 281, 13777–13783 (2006).
8. Pullman, M. E. & Monroy, G. C. A Naturally Occurring Inhibitor of Mitochondrial Adenosine Triphosphatase. The journal of biological chemistry 238, 3762–3769 (1963).
9. Campanella, M., Parker, N., Tan, C. H., Hall, A. M. & Duchen, M. R. IF1(−): setting the pace of the F(1)F(0)-ATP synthase. Trends Biochem Sci 34, 343–350 (2009).
10. Rouslin, W. & Pullman, M. E. Protonic inhibition of the mitochondrial adenosine 5′-triphosphatase in ischemic cardiac muscle. Reversible binding of the ATPase inhibitor protein to the mitochondrial ATPase during ischemia. Journal of molecular and cellular cardiology 19, 661–668 (1987).
11. Sah, J. F., Kumar, C. & Mohanty, P. pH dependent conformational changes modulate functional activity of the mitochondrial ATPase inhibitor protein. Biochem Biophys Res Commun 194, 1521–1528 (1993).
12. Fujikawa, M., Inamura, H., Nakamura, J. & Yoshida, M. Assessing Actual Contribution of IF1, Inhibitor of Mitochondrial FoF1, to ATP Homeostasis, Cell Growth, Mitochondrial Morphology, and Cell Viability. The journal of biological chemistry 287, 18781–18787 (2012).
13. Grover, G. J. et al. Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolyse activity. Am J Physiol Heart Circ Physiol 287, H1747–1755 (2004).
14. Grover, G. J. & Malm, J. Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolyse inhibitor BMS-199264 in myocardial ischemia. Cardiovasc Ther 26, 287–296 (2008).
15. Formentini, L. et al. In vivo inhibition of the mitochondrial H+ – ATP synthase in neurons promotes metabolic preconditioning. EMBO J, (2014).
16. Shah, D. I. et al. Mitochondrial Atpip1 regulates haem synthesis in developing erythroblasts. Nature 491, 608–612 (2012).
17. Chen, W. W. et al. Inhibition of ATPIF1 Ameliorates Severe Mitochondrial Respiratory Chain Dysfunction in Mammalian Cells. Cell reports 7, 27–34 (2014).
18. Nakamura, J., Fujikawa, M. & Yoshida, M. IF1, a natural inhibitor of mitochondrial ATP synthase, is not essential for the normal growth and breeding of mice. *Biosci Rep* **33**, (2013).
19. Gledhill, J. R., Montgomery, M. G., Leslie, A. G. & Walker, J. E. How the regulatory protein, IF(1), inhibits F(1)-ATPase from bovine mitochondria. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 15671–15676 (2007).
20. Campanella, M. et al. Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1. *Cell metabolism* **8**, 13–25 (2008).
21. Grover, G. J., Marone, P. A., Koetzner, L. & Seto-Young, D. Energetic signalling in the control of mitochondrial F1Fo ATP synthase activity in health and disease. *The International Journal of Biochemistry & Cell Biology* **40**, 2698–2701 (2008).
22. Song, R. et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-kappaB drives hepatocellular carcinoma angiogenesis and metastasis. *Hepatology* **60**, 1659–1673 (2014).
23. Purcell, N. H. et al. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. *Proceedings of the National Academy of Sciences of the United States of America* **98**, 6668–6673 (2001).
24. Frantz, S. et al. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. *Cardiovasc Res* **57**, 749–756 (2003).
25. Garcia-Bermudez, J. et al. PKA Phosphorylates the ATPase Inhibitory Factor 1 and Inactivates Its Capacity to Bind and Inhibit the Mitochondrial H(+)-ATP Synthase. *Cell reports* **12**, 2143–2155 (2015).
26. Jennings, R. B., Reimer, K. A. & Steenbergen, C. Effect of inhibition of the mitochondrial ATPase on net myocardial ATP in total ischaemia. *Journal of molecular and cellular cardiology* **23**, 1383–1395 (1991).
27. Faccenda, D. et al. Control of Mitochondrial Remodeling by the ATPase Inhibitory Factor 1 Unveils a Pro-survival Relay via OPA1. *Cell reports* **18**, 1869–1883 (2017).
28. Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nature cell biology* **13**, 132–141 (2011).
29. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* **12**, 1–222 (2016).
30. He, L. et al. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. *Circulation* **126**, 1705–1716 (2012).
31. Brookes, P. S. et al. Increased sensitivity of mitochondrial respiration to inhibition by nitric oxide in cardiac hypertrophy. *Journal of molecular and cellular cardiology* **33**, 69–82 (2001).
32. Wittig, I., Karas, M. & Schagger, H. High resolution clear native electrophoresis for in-gel functional assays and fluorescence studies of membrane protein complexes. *Mol Cell Proteomics* **6**, 1215–1225 (2007).
33. Wang, P. et al. Peroxisome proliferator-activated receptor (delta) is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart. *Circulation research* **106**, 911–919 (2010).
34. Liu, J. et al. Peroxisome Proliferator-Activated Receptor (beta)/(delta) Activation in Adult Hearts Facilitates Mitochondrial Function and Cardiac Performance Under Pressure-Overload Condition. *Hypertension* **57**, 223–230 (2011).

**Acknowledgements**

We thank the technical services provided by the UAB Diabetes Research Center Bioanalytical Redox Biology and Small Animal Phenotyping Cores (P30DK079626), UAB Comprehensive Diabetes Center. This work was supported by grants from American Heart Association (Q.Y., Grant-in-Aid #14GRNT20490216), American Diabetes Association (Q.Y., #8-12-BS-208 and #1-17-IBS-184), NIH (R01 HL13533 and R03AG055899), National Natural Science Foundation of China (81570366 to Q.Y and 81500312 to Q.L) and Raman Fellowship for Post-Doctoral Research in USA from the University Grants Commission, Govt. of India (2014–15) to KS.

**Author Contributions**

K.Y. and Q.Y. proposed and designed the study. K.Y., Q.L., K.S., and F.H. performed main experiments. S.P. provided human heart samples and the related experimental design. M.Y. provided mice and assessment of experimental design. K.Y., Q.L., L.Z., S.P and Q.Y. conducted data analysis and interpretation. K.Y. and Q.Y. wrote the paper. All authors reviewed the manuscript.

**Additional Information**

Supplementary information accompanies this paper at doi:10.1038/s41598-017-11251-8

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.